Get started
Author

Joseph P. Sanderson

Observed names: Joseph P Sanderson, Joseph Sanderson, Sanderson, Joseph Peter
ORCID: 0000-0002-1206-8833
Observed ORCID: 0000-0002-1206-8833
OpenAlex ID: A5046364897
Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals
2011 · Patrick J Brennan, Raju V V Tatituri, et al. · Nature Immunology · 336
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
2023 · David S. Hong, Brian A. Van Tine, et al. · Nature Medicine · 218
PDF
Activation of T cells by carbamazepine and carbamazepine metabolites
2006 · Ying Wu, Joseph P. Sanderson, et al. · Journal of Allergy and Clinical Immunology · 135
PDF
Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling
2007 · Joseph P Sanderson, Dean J Naisbitt, et al. · The Journal of Immunology · 127
PDF
Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy
2019 · Joseph P Sanderson, Darragh J Crowley, et al. · OncoImmunology · 101
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules
2018 · Jane Harper, Katherine J. Adams, et al. · PLoS ONE · 87
PDF
Innate-Like Control of Human iNKT Cell Autoreactivity via the Hypervariable CDR3β Loop
2010 · Gediminas Matulis, Joseph P. Sanderson, et al. · PLoS Biology · 77
PDF
Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate
2018 · Ellen C. Border, Joseph P. Sanderson, et al. · OncoImmunology · 71
PDF
β-Lactam Antibiotics Form Distinct Haptenic Structures on Albumin and Activate Drug-Specific T-Lymphocyte Responses in Multiallergic Patients with Cystic Fibrosis
2013 · Rosalind E. Jenkins, Fiazia S. Yaseen, et al. · Chemical Research in Toxicology · 61
Role of bioactivation in drug-induced hypersensitivity reactions
2006 · Joseph P. Sanderson, Dean J. Naisbitt, et al. · The AAPS Journal · 61
PDF
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10 + advanced non-small cell lung cancer
2022 · George R Blumenschein, Siddhartha Devarakonda, et al. · Journal for ImmunoTherapy of Cancer · 57
PDF
Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver Cancer
2018 · Roslin Y. Docta, Tiago Ferronha, et al. · Hepatology · 54
PDF
Structural and Functional Changes of the Invariant NKT Clonal Repertoire in Early Rheumatoid Arthritis
2015 · Salah Mansour, Anna S Tocheva, et al. · The Journal of Immunology · 34
CD 1d protein structure determines species‐selective antigenicity of isoglobotrihexosylceramide (i G b3) to invariant NKT cells
2012 · Joseph P. Sanderson, Patrick J. Brennan, et al. · European Journal of Immunology · 32
PDF
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients
2024 · Tianjiao Wang, Jean-Marc Navenot, et al. · Molecular Therapy — Methods & Clinical Development · 23
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors
2022 · David S. Hong, Marcus O. Butler, et al. · Frontiers in Oncology · 21
PDF
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β
2021 · Jonathan D Silk, Rachel J M Abbott, et al. · The Journal of Immunology · 21
PDF
Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy
2025 · Gabrielle Knafler, Alan L. Ho, et al. · Cancer Treatment Reviews · 20
PDF
Enhancing Efficacy of TCR-engineered CD4+ T Cells Via Coexpression of CD8α
2023 · Victoria E. Anderson, Sara S. Brilha, et al. · Journal of Immunotherapy · 19
T-cell populations in chronic pancreatitis
2015 · James Jupp, Salah Mansour, et al. · Pancreatology · 15
The Clonal Invariant NKT Cell Repertoire in People with Type 1 Diabetes Is Characterized by a Loss of Clones Expressing High-Affinity TCRs
2017 · Anna S Tocheva, Salah Mansour, et al. · The Journal of Immunology · 14
Drugs as Haptens, Antigens, and Immunogens
2007 · B. Kevin Park, Joseph P. Sanderson, et al. · KARGER eBooks · 13
Natural variations at position 93 of the invariant Vα24‐Jα18 α chain of human iNKT‐cell TCRs strongly impact on CD1d binding
2011 · Joseph P. Sanderson, Kathrin Waldburger‐Hauri, et al. · European Journal of Immunology · 12
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
2016 · Andreas Lundqvist, Vincent van Hoef, et al. · Journal for ImmunoTherapy of Cancer · 11
PDF
Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury
2011 · Sabah El-Ghaiesh, Joseph P. Sanderson, et al. · Journal of Allergy and Clinical Immunology · 11
Works count: 40
Citation count: 1,657
H-index: 19
I10-index: 25
Year
Topic
Type